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Abstract
Introduction: More than half of those with chronic diseases, including osteoporosis, discontinue treatment during the first year of its
administration. This problem increases over the course of continued follow-up. Additionally, it has been observed that 13% of women,
prescribed oral daily alendronate, do not even start the treatment, while 20% of patients discontinue the therapy during the first four
months. On the other hand, those patients who are compliant achieve increased bone mass density with a simultaneous decrease of
fracture risk. The aim of our study was to assess the adherence to the recommended alendronate 70 administration protocol over the
course of 12 months by women with post-menopausal osteoporosis.
Material and methods: Adherence (compliance plus persistence) to alendronate 70 therapy was assessed in a prospective study of 153
post-menopausal women, followed up for one year with monitoring every two months.
Results: Adherence to therapy of all the study participants was high during the entire study period, the patients remaining compliant
after a year in 95.08 ± 1.39% (mean ± SEM) of cases, and the mean persistence with medication was 347.05 ± 5.07 days. In the group of
patients who interrupted treatment, the mean persistence was 212.44 days. One of the study participants did not start the treatment, and
another two discontinued the therapy within 30–60 days of the study onset (between the first two visits). Facilitated contacts with the
doctor, continuous access to prescribed treatment and frequent visits significantly improved patient compliance. The common reason for
discontinuation was side effects, while age (but not education) affected the rate of compliance with therapy. The worst results were
obtained in the group of patients with osteoporosis diagnosed more than five years before the study, particularly in the subgroup where
alendronate was being used for the first time or where treatment resumed after a substantial break.
Conclusions: The obtained results indicate that better adherence to alendronate 70 therapy, administered once a week, depends on more
frequent monitoring of treated patients. (Pol J Endocrinol 2011; 62 (1): 24–29)
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Streszczenie
Wstęp: Wykazano, że ponad 50% pacjentów leczonych z powodu chorób przewlekłych, w tym osteoporozy, przerywa terapię w ciągu
pierwszego roku jej stosowania. Problem ten narasta z czasem trwania obserwacji. Stwierdzono, że 13% pacjentów z osteoporozą w ogóle
nie rozpoczyna leczenia, a ponad 20% przerywa terapię w ciągu pierwszych 4 miesięcy trwania choroby. Wykazano, że przestrzeganie
przez pacjentów wprowadzonej terapii osteoporozy poprawia gęstość mineralną kości i zmniejsza ryzyko złamań.
Celem pracy była ocena, w rocznym badaniu prospektywnym, stopnia przestrzegania zaleceń długotrwałej terapii preparatem alendro-
nian 70 przez pacjentki leczone z powodu osteoporozy.
Materiał i metody: Ocenie poddano 153 pacjentki w wieku 48–89 lat z rozpoznaną osteoporozą leczone alendronianem 70 mg, jeden raz
w tygodniu, przez okres roku. Pacjentki monitorowano co 2 miesiące. Wzięto pod uwagę czas trwania choroby, ciągłość i systematyczność
przyjmowania leków oraz przyczynę przerwania stosowanego leczenia.
Wyniki: Podczas trwania badania stopień przestrzegania zasad terapii u wszystkich uczestniczek badania był wysoki i łącznie systema-
tyczność po roku utrzymało 95,08 ± 1,39% (średnia ± SEM), a średnia długość przyjmowania leków wyniosła 347,05 ± 5,07 dni. W grupie
pacjentek, które przerwały leczenie średni okres stosowania się do zaleceń wyniósł 212,44 dnia. Z całej grupy jedna pacjentka w ogóle nie
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podjęła leczenia, 2 przerwały w okresie 30–60 dni stosowania, czyli między 2 kolejnymi wizytami. Ułatwienie pacjentowi kontaktu
z lekarzem, stały dostęp do leku oraz częste wizyty w znaczny sposób poprawiają stosowanie się pacjentów do zaleceń. Najczęstszą
przyczyną przerwania leczenia były działania niepożądane stosowanego preparatu. Wiek, lecz nie wykształcenie, miały wpływ na prze-
strzeganie terapii. Najgorsze wyniki uzyskano w grupie pacjentek z rozpoznaniem osteoporozy dłuższym niż 5 lat, szczególnie w pod-
grupie, u której włączono alendronian 70 pierwszy raz lub podjęto leczenie po przerwie.
Uzyskane wyniki wskazują na fakt lepszego przestrzegania zaleceń lekarskich przez pacjentów leczonych z powodu osteoporozy
w trakcie dobrego monitorowania terapii preparatem cotygodniowym. Krytycznymi momentami decydującymi o przerwaniu leczenia
były objawy niepożądane związane z terapią.
Wnioski: W przeprowadzonym badaniu wykazano, że częstsze monitorowanie w znaczący sposób poprawia przestrzeganie zasad tera-
pii alendronianem stosowanym w dawkach cotygodniowych. (Endokrynol Pol 2011; 62 (1): 24–29)
Słowa kluczowe: osteoporoza, systematyczność, ciągłość, alendronian 70, przyczyny przerwania terapii
The study was sponsored by the Scholaris Foudation and the Foundation for the Development of Polish Pharmacy and Medicine (Medical
University Grant No. 501-91-269).
Introduction
Osteoporosis is a major public health problem in many
countries, including Poland [1]. Currently available
treatment options serve to increase bone mineral den-
sity (BMD) and decrease fracture risk [2–7]. In order to
obtain the benefits of medication, treated patients
should maintain optimal compliance and persistence
with their osteoporosis therapy [8–10], since, in the
words of C. Everett Koop, the former US Surgeon Gen-
eral: “Drugs don’t work in patients who don’t take
them.” There are some negative consequences of poor
adherence (compliance + persistence) to oral osteoporo-
sis treatment [11–15].
It has been shown that more than 50% of people with
chronic diseases, especially in their subclinical stages,
including osteoporosis, hypertension and hypercholes-
terolaemia, discontinue treatment during the first year
of its administration [16]. Many patients take drugs in-
correctly, infrequently, or do not take them at all. This
problem increases over the course of continued follow-
up. It has been found that 13% of women prescribed
daily oral alendronate did not even start the treatment
and 20% of patients discontinued the therapy during
the first four months [17, 18].
Longitudinal, retrospective analyses of large data-
bases indicate that adherence to recommended os-
teoporosis therapies is less than optimal. Persistence on
daily bisphosphonate therapy has been observed in
25–35% of patients during the first year of its adminis-
tration. The persistence with weekly bisphosphonate
treatment has been better, ranging between 35% and
45% [12].
The problem does not depend on the form of treat-
ment [12]. Boguzzi et al. [19] presented the results of
a study involving a cohort of 10,566 women, showing
that their adherence during the first year was higher
with two bisphosphonates: daily alendronate (60.7%)
and daily risedronate (58.4%), while lower with ralox-
ifene (53.9%). The persistence rate was, however, poor
for all the agents (daily alendronate 23%, daily risedr-
onate 19.4%, and raloxifene 16.2%). A somewhat high-
er persistence level during the first 12 months has been
presented in other papers [20]. In three examined coun-
tries, the compliance was as follows: United States 32%,
UK 40%, and France 44%. Women on daily alendronate
persisted with treatment for 185 days in the United
States, 208 in the United Kingdom and 155 in France
[20]. The persistence curves for osteoporosis medica-
tions showed a rapid decrease within the first three
months of therapy [17–19]. Similarly, a retrospective
study of post-menopausal women, who used daily al-
endronate, calcitonin, HRT, raloxifene or risedronate,
showed their compliance below 66% over a 60-day pe-
riod [21]. Adherence to medication recommendations
in cases of osteoporosis is very important because rates
of compliance with recommended therapy below 66%
result in suboptimal outcomes regarding bone mineral
density [22].
In our previous study, compliance to daily alendr-
onate therapy was assessed for six or 18 months in clin-
ical practice of post-menopausal osteoporosis [15]. Us-
ing a retrospective study of medical records at our uni-
versity hospital’s Outpatient Clinic, as well as telephone
interviews with patients, compliance of post-menopaus-
al patients with daily alendronate regimen was assessed.
After 18 months of observation, 20.4% of patients, and
after 6 months 8.5%, of patients, discontinued their
treatment as a result of intolerance especially side ef-
fects from the gastrointestinal tract (47.8% of those dis-
continuing), health problems unrelated to osteoporo-
sis (8.7%), finding the daily regimen inconvenient
(13.1%), the costs of therapy (4.3%) and a less than ex-
pected improvement in clinical condition  (26.1%). It is
worth mentioning that in both periods of observation
(18 months and six months), almost the same percent-
age of patients stopped their consultations at our Out-
patient Clinic (15.6% and 14.4%, respectively). Tele-
phone interviews with the patients who stopped at-
tending the Outpatient Clinic at the Regional Centre of
Menopause and Osteoporosis revealed that more than
50% of them discontinued the treatment.
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The aim of this study was to assess the adherence
rate to weekly alendronate therapy, administered for
12 months to women with post-menopausal osteoporo-
sis, by monitoring them every two months.
Material and methods
Based on a prospective study of 153 post-menopausal
women aged between 48 and 89, the compliance and
persistence to alendronate 70 therapy was assessed
during one year follow-up, with monitoring of all the
patients every two months. Of the participating women,
61 were either antiresorptive drug-naïve or had had at
least a one year break in therapy before the study on-
set. All of them were informed about osteoporosis and
signed a consent form to participate in the study. Bone
mineral density £ –2.5 SD in hip or spine and/or os-
teoporotic fracture(s), diagnosed or in history, were the
inclusion criteria.
Single factor variance analysis was applied with the
NIR Fisher Test for the patient’s age, education and the
time of diagnosis. Student-t test was used for the other
parameters.
Results
After one year of the study period, the compliance rate
of all the study participants was high, amounting to
95.08%. The mean persistence with medication was
347.05 ± 5.08 days (Table I). The grouping of patients
by age is shown in Figure 1. In the group of patients
who interrupted treatment, the mean persistence was
212.44 days. The patients aged 60–69 (Table I) demon-
strated better compliance than any other age group, but
statistically significant difference between 60–69 and
70–79 was observed. The lowest compliance and per-
sistence (although not statistically significant) were ob-
served in the group of patients who had reached voca-
tional education (Table II). The lowest compliance and
persistence were also found in the group of patients
with osteoporosis diagnosed more than five years be-
fore the study (Table III), especially in the subgroup
where alendronate 70 was either introduced for the first
time or re-administered after discontinuation (Table IV).
In assessing very good compliance and persistence, it
was found that doctors from regional centres were more
effective than those at the Outpatient Clinic of the Med-
ical University (Table V).
Facilitation of patient contacts with the doctor, con-
tinuous access to prescribed medication and frequent
visits considerably improved the patients’ adherence to
prescribed recommendations. The commonest reasons
for discontinuation of treatment were adverse effects
of an applied agent and hospitalisation (Table VI).
Discussion
Osteoporosis is a chronic disease, demanding long-term
clinical observations and strict adherence to medication
regimens.
Table I. Compliance and persistence in different age groups. Significance: ***p < 0.05 compared to group aged 70–79
Tabela I. Systematyczność i ciągłość terapii w grupach wiekowych. Znamienność: ***p < 0,05 w porównaniu z grupą wiekową 70–
–79 lat
Age group Number of patients Compliance in % Persistence (days of treatment
(mean ± SEM)  during one year) (mean ± SEM)
< 59 25 94.25 ± 3.04 344 ± 11.1
60–69 41 99.6 ± 0.28*** 363.54 ± 1.02***
70–79 66 92.73 ± 2.64 338.45 ± 9.63
80–89 21 94.66 ± 4.43 345.52 ± 16.16
Total 153 95.08 ± 1.39 347.05 ± 5.08
Figure 1. Age ranges of the study participants (%)
Rycina 1. Podział pacjentek na grupy wiekowe (%)
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Table II. Compliance and persistence of patients depending on their educational level
Tabela II. Systematyczność i ciągłość terapii w zależności od poziomu wykształcenia
Educational level Number of patients Compliance % Persistence (days of treatment
(mean ± SEM)  during one year) (mean ± SEM)
Primary 36 97.34 ± 1.94 355.31 ± 7.07
Vocational 40 92.73 ± 3.14 338.47 ± 11.46
Secondary 47 93.99 ± 3.16 343.06 ± 11.52
University 30 97.21 ± 1.77 354.83 ± 6.48
Total 153 95.08 ± 1.39 347.05 ± 5.08
Table III. Compliance and persistence of patients after one year of observation, depending on time since the diagnosis of
osteoporosis. Significance: ***p < 0.05 compared to Group 3
Tabela III. Systematyczność i ciągłość terapii po roku leczenia w zależności od czasu rozpoznania osteoporozy. Znamienność:
***p < 0,05 w porównaniu z grupą 3
Time since the diagnosis Number of Compliance in % Persistence (days of treatment
of osteoporosis patients (mean ± SEM)  during one year) (mean ± SEM)
1. One month 27 95.33 ± 3.06 347.96 ± 11.15
2. One year 21 97.98 ± 1.66 357.62 ± 6.05
3. More than one year, but less than five years 72 97.03 ± 1.62 354.15 ± 5.86
4. ≥ 5 years 33 88.79 ± 4.60*** 324.10 ± 16.79***
Total 153 95.08 ± 1.39 347.05 ± 5.08
Table IV. Compliance and persistence of patients after one year of therapy, including the first time alendronate 70 (ALE 70)
users and the participants taking the drug again after at least a one year break. Significance: ***p < 0.05 compared to group of
patients continuing therapy with ALE 70
Tabela IV. Systematyczność i ciągłość po roku terapii z podziałem na pacjentki w trakcie stosowania leku lub pacjentki
stosujące ALE70 pierwszy raz lub po co najmniej 1 rocznej przerwie. Znamienność: ***p < 0,05 w porównaniu z grupą pacjentek
kontynuującą terapię alendronianu 70
Patient type Number of Compliance in % Persistence (days of treatment
patients (mean ± SEM)  during one year) (mean ± SEM)
Patients continuing therapy with ALE 70 92 95.68 ± 1.51 349.22 ± 5.51
First time ALE 70 users and participants
taking the drug after a break 61 94.19 ± 2.66 343.79 ± 9.7***
Table V. Compliance and persistence of patients, treated by physicians at the Outpatient Clinic of the Medical University and
at regional centres. Significance: ***p < 0.05
Tabela V. Systematyczność i ciągłość terapii z podziałem na lekarzy pracujących w Poradni Uniwersyteckiej lub Poradni
Regionalnej. Znamienność: ***p < 0,05
Venue Number of Number of first Compliance in % Persistence (days of treatment
patients  time ALE 70 users  (mean ± SEM)  during one year) (mean ± SEM)
Medical University 77 32 91.55 ± 2.59 334.14 ± 9.46
Regional centres 76 29 98.67 ± 0.81*** 360.13 ± 2.96***
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Unexpectedly, in the reported study, the compliance
with alendronate 70 therapy, administered every week
in the clinical practice of osteoporosis, was very good.
An analysis of seven visits during one year demonstrat-
ed 95.08% of patients with osteoporosis, who had been
treated before and after our initial consultation,  con-
tinued their treatment. The main reasons for therapy
discontinuation were side effects (61.10%) and infections
or hospitalisations (16.67%). Data from our previous
retrospective study showed that, after 18 months of
observation, 20.4% of patients and, after six months,
8.5% of patients, discontinued their treatment [15]. It is
worth mentioning that in both periods of observation, al-
most the same percentage of patients stopped attending
our Outpatient Clinic (15.6% and 14.4%, respectively).
Telephone interviews with those patients revealed that
more than 50% of them had discontinued the treatment.
The results of our paper can be compared to the
work of a Canadian group [23]. The Canadian Database
of Osteoporosis and Osteopenia (CANDOO), a prospec-
tive observational database designed to capture clinical
data, was searched for patients who started therapy,
with 1,196 initiating etidronate, 477 alendronate thera-
py for women and men and 294 hormone replacement
therapy for women. After one year, 90.3% of those pa-
tients were still taking etidronate, compared to 77.6%
on daily alendronate and 80.1% of patients on HRT,
which decreased to 44.5% after six years. Reginster and
Lecart [24] suggest that the persistence rates in the CAN-
DOO study may be artificially high. The study took
place in a clinic, where the patients initially signed
a consent form and were given verbal encouragement
to continue treatment. Our observations were similar
to the prospective CANDOO study.
In several reports, persistence scores are far from
encouraging. For example, medication persistence was
demonstrated in only 39.0% of the patients receiving
daily alendronate therapy at month 12 of one study
period [25]. In a questionnaire study of 219 women with
osteoporosis and on daily risedronate, one in four did
not comply correctly with dosing instructions, despite
counselling [26]. Using a telephone interview survey in
a subsequent study, it was reported that within 13 months
of observation of 812 women with osteoporosis, treat-
ed with daily alendronate, 56% of the patients were non-
compliant [27].
Good adherence to osteoporosis treatment is very
important for the effectiveness of administered medica-
tions. Among 999 responding patients with osteoporo-
sis, effectiveness was ranked as by far the most impor-
tant determinant of preference (79%), followed by the
time on the market (14%), dosing procedure (4%) and
dosing frequency (3%). An incorporation of patient
preferences into the medication decision-making pro-
cess could enhance patient compliance and clinical out-
comes [28]. This is very important, as it has been shown
that compliance rates below 66% in drug treatment
result in sub-optimal improvement in bone density
[22]. On the other hand, better compliance in the ac-
tual practice may significantly decrease osteoporosis-
related fracture risks (16% over two years) [29]. It has
been observed that the anti-fracture effectiveness asso-
ciated with high adherence to oral bisphosphonates,
varies substantially by age and fracture type [30]. Caro
et al. [31] showed that poorly compliant patients were
significantly more often hospitalised (53.4%) compared
to compliant ones (42.6%), leading to a 14% increase in
the costs of medical services.
In our analysis, the main reason for discontinuation
of weekly alendronate treatment were side effects, espe-
cially from the gastrointestinal tract (61.10%), infections
(16.67%), and fracture (5.56%). One person did not start
therapy (5.56%) and other causes were 11.11%, these re-
sults being similar to those of other authors [22, 32].
Among patients completing another study (4,231),
the percentages of high compliance patients were: 80%
(raloxifene), 79% (daily alendronate), 65% (weekly al-
endronate) and 76% (risedronate). Discontinuation, due
to side effects, was highest for weekly alendronate
(7.0%), followed by daily alendronate (6.4%), raloxifene
(3.8%) and risedronate (3.4%). The discontinuation rate
was higher for patients with a history of surgical meno-
pause, advanced age, and a lack of knowledge about
the medical prevention of osteoporosis [33].
Claxton et al. [34] has suggested that the prescribed
number of doses per day is inversely related to compli-
ance. In other words, less frequent dosing regimens result
in better compliance across a variety of therapeutic class-
es. This is reflected in osteoporosis therapy. Post-meno-
pausal women, prescribed a weekly regimen of bisphos-
phonates, demonstrated significantly higher compliance
rates than daily regimen patients, and they also persisted
longer with treatment. However, compliance and persis-
tence rates were suboptimal for both regimens [20, 35].
Table VI. Reasons for non-compliance (%)
Tabela VI. Przyczyny przerwania terapii (%)
Reasons for non-compliance Number of %
patients
Side effects 11 61.10
Infection/hospitalisation 3 16.67
Fractures 1 5.56
Failure to start treatment 1 5.56
Other 2 11.11
Total 18 100
29
Endokrynologia Polska/Polish Journal of Endocrinology 2011; 62 (1)
PR
A
C
E 
O
R
Y
G
IN
A
LN
E
Osteoporosis is a chronic disease which needs long-
term clinical monitoring and strict adherence to thera-
peutic recommendations.
Analysing our observations and the results of oth-
ers, we suggest that the main reasons for discontinua-
tion of treatment are not only digestive incidents but
also problems with obtaining prescriptions within the
first three months of treatment, dissatisfaction with ther-
apy results, and poor monitoring.
In our opinion, effective communication and more
frequent follow-up visits would greatly improve the
adherence to osteoporosis treatment modalities.
Our study showed that monitoring, performed ev-
ery two months, was very helpful both for compliance
and persistence scores. Variations in adherence to the
medical treatment of osteoporosis may also depend on
other factors: an individual patient’s convictions, a pa-
tient’s social and economic conditions, physical predis-
positions or health problems, age, and the time elapsed
since the diagnosis of osteoporosis, which was present-
ed in our study. Compliance could be improved by pa-
tients choosing their treatment regimen. It is of utmost
importance that patients are informed about diagnosis
results and their long-term treatment plan, highlight-
ing the role of persistence with therapy and compliance
with dosing recommendations [36]. Adherence to drug
administration regimens in the therapy of osteoporosis
improves BMD, reduces femoral neck and spine frac-
ture risks, while also decreasing the costs of inpatient
therapy. Some data suggests that psychobehavioural
interventions may help improve patient motivation [8].
Conclusions
Good adherence to medical recommendations by pa-
tients treated for osteoporosis with alendronate 70 de-
pends on fairly frequent monitoring visits. The critical
points, decisive for treatment discontinuation, include
therapy-induced adverse effects.
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